"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 13 | 2 | 15 |
| 1997 | 6 | 1 | 7 |
| 1998 | 22 | 4 | 26 |
| 1999 | 9 | 8 | 17 |
| 2000 | 17 | 6 | 23 |
| 2001 | 24 | 6 | 30 |
| 2002 | 34 | 11 | 45 |
| 2003 | 29 | 11 | 40 |
| 2004 | 35 | 12 | 47 |
| 2005 | 30 | 18 | 48 |
| 2006 | 33 | 21 | 54 |
| 2007 | 39 | 16 | 55 |
| 2008 | 31 | 18 | 49 |
| 2009 | 39 | 21 | 60 |
| 2010 | 52 | 27 | 79 |
| 2011 | 63 | 17 | 80 |
| 2012 | 55 | 28 | 83 |
| 2013 | 53 | 23 | 76 |
| 2014 | 76 | 20 | 96 |
| 2015 | 84 | 33 | 117 |
| 2016 | 59 | 31 | 90 |
| 2017 | 59 | 26 | 85 |
| 2018 | 49 | 26 | 75 |
| 2019 | 42 | 23 | 65 |
| 2020 | 38 | 22 | 60 |
| 2021 | 46 | 15 | 61 |
| 2022 | 24 | 3 | 27 |
| 2023 | 40 | 0 | 40 |
| 2024 | 20 | 24 | 44 |
| 2025 | 23 | 6 | 29 |
| 2026 | 21 | 3 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. Drugs. 2026 Sep; 86(9):1513-1533.
-
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026 07 28; 10(14):4923-4930.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis. J Neurooncol. 2026 Jul 15; 178(3).
-
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul; 10(7):e2600456.
-
Nephrotoxicity of conventional chemotherapeutics: part 1-platinum compounds and antimetabolite agents. Nephrol Dial Transplant. 2026 May 29; 41(6):1011-1022.
-
Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort. ESC Heart Fail. 2026 05 05; 13(3).
-
Nephrotoxicity of conventional chemotherapeutics: part II-non-platinum agents and miscellaneous nephrotoxic drugs. Nephrol Dial Transplant. 2026 Apr 30; 41(5):828-838.
-
Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure. J Ovarian Res. 2026 Apr 25; 19(1).
-
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr; 10(4):e2500985.